Imago is committed to developing true differentiating therapies by focusing on eradicating stem cells responsible for myeloid malignancies. Imago BioSciences is currently conducting clinical studies of its lead molecule IMG-7289 in myeloid cancers and related neoplastic diseases.
Myeloid malignancies, blood cell cancers arising in the bone marrow, have long been associated with disruptions of epigenetic regulation. There are many clinical versions of myeloid diseases, all of which can evolve into life-threatening phases. As with other cancers, several different types of agents may be needed to bring myeloid diseases under control.
The first-in-patient study of IMG-7289 was initiated in late 2016 in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. The multiple-ascending dose Phase 1 portion of that study was concluded in 2017. The Phase 2 portion of the study of IMG-7289 in combination with all-trans retinoic acid (ATRA) was recently completed.
A Phase 2b study of IMG-7289 in patients with high risk myelofibrosis is currently enrolling patients globally.